Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for the clinical trial of Ruvelimab tablets, which will soon commence phase III trials for prostate cancer treatment [1] Group 1: Clinical Trial Approval - The National Medical Products Administration approved the clinical trial application for Ruvelimab tablets on August 26, 2025, allowing the company to conduct phase III clinical trials for prostate cancer [1] - Ruvelimab tablets are classified as a second-generation AR inhibitor, offering stronger AR inhibition without androgenic effects compared to first-generation inhibitors [1] Group 2: Market Context - Ruvelimab tablets were approved for market release in 2022 for treating high tumor burden metastatic hormone-sensitive prostate cancer (mHSPC) patients [1] - Competing second-generation AR inhibitors currently available in the market include Enzalutamide, Apalutamide, and Darolutamide [1] - According to EvaluatePharma, the global sales of similar products are projected to reach approximately $11.037 billion in 2024 [1] Group 3: Research Investment - The total research and development investment for Ruvelimab tablets has reached approximately 693.09 million yuan [1]